{"product_id":"enlonstobart","title":"Enlonstobart","description":"\u003cp\u003eEnlonstobart, a recombinant, fully humanised immunoglobulin G4 monoclonal antibody targeted against programmed cell death protein 1 (PD-1), is being developed by the CSPC Pharmaceutical Group for the treatment of advanced cervical cancer and other solid tumours.\u003c\/p\u003e\u003cul\u003e\u003cli\u003e\n\u003cspan data-huuid=\"5813577302449632437\"\u003eEnlonstobart \u003c\/span\u003esold under the brand name 恩舒幸 (Enshuxing) ® in china. \u003c\/li\u003e\u003c\/ul\u003e\u003cp\u003eEnlonstobart received its first approval (a conditional marketing authorisation) in June 2024, in China, for use in patients with recurrent or metastatic programmed cell death ligand 1 (PD-L1)-positive cervical cancer who have failed previous platinum-containing chemotherapy. \u003c\/p\u003e","brand":"CSPC Pharmaceutical Group, China","offers":[{"title":"Default Title","offer_id":44797956915243,"sku":"RL3220250101","price":0.0,"currency_code":"AMD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0701\/3528\/3755\/files\/2025-01-1067.jpg?v=1787022272","url":"https:\/\/xomeds.com\/products\/enlonstobart","provider":"XOMEDS","version":"1.0","type":"link"}